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Abstract
Purpose of review The purpose of this review is to highlight the molecular and clinical
characteristics of the cryopyrin-associated periodic fever syndrome (CAPS) and its man-
agement. CAPS is an autosomal dominantly inherited autoinflammatory disorder associ-
ated with mutations in the NLRP3 gene, which ultimately lead to excessive production of
interleukin-1β (IL-1β) and systemic inflammation. Typical systemic features include fever,
urticarial rash and arthralgia, and ultimately amyloidosis. There are also multiple neuro-
logical manifestations including, but not restricted to, headache, sensorineural hearing
loss, aseptic meningitis, myalgia and optic nerve involvement.
Recent findings Since the recognition of CAPS as a single disease entity and discovery of
the underlying causative gene, there has been a major breakthrough in terms of its
treatment by pharmacological IL-1β inhibition. Highly targeted therapies against IL-1
have been shown to be remarkably effective in the treatment of CAPS and make early
diagnosis of this condition crucial. It is hoped that starting pharmacological intervention
in a timely manner will prove neuroprotective. There are three drugs licensed for treatment
of CAPS; canakinumab, anakinra and rilonacept. The former two are widely used:
canakinumab is a fully humanised anti-IL-1β monoclonal antibody administered as a
subcutaneous injection once every 8 weeks starting at a dose of 150 mg in patients
weighing more than 40 kg. Anakinra is a recombinant form of the IL-1 receptor antagonist
and the adult daily dose is 100 mg subcutaneously.
Summary CAPS is a highly debilitating disorder characterised by unregulated IL-1β
production driven by autosomal dominantly inherited mutations in the NLRP3 gene.
Effective therapies targeted against IL-1 are now available and are vital to prevent long-
term complications.
Introduction
The cryopyrin-associated periodic fever syndrome (CAPS)
is amultisystemgenetic autoinflammatory disorder, which
has a wide range of systemic as well as neurological man-
ifestations. The cardinal symptoms of CAPS include epi-
sodes of fever, urticarial rash, red eyes and arthralgia [1],
whilst neurological manifestations include headache, sen-
sorineural hearing loss and optic nerve involvement [2••,
3, 4]. At the turn of the twenty-first century, the discovery of
a common genetic locus, theNLRP3 gene on chromosome
1q44, resulted in the recognition that a number of previ-
ously described clinical syndromes, including chronic in-
fantile neurological, cutaneous and articular syndrome
(CINCA), Muckle-Wells syndrome (MWS) and familial
cold autoinflammatory syndrome (FCAS) were part of a
wider clinical entity. The term CAPS began to gain recog-
nition to describe the spectrum of autosomal dominant
and apparently sporadic diseases caused by mutations in
NLRP3 [5, 6].
CAPS is rare and is estimated to affect one to three
people per million of the population with no specific
demographic predilection identified [7]. A large Eu-
ropean registry [8••] has provided key clinical data
regarding CAPS. Median age at onset was 0.8 years
(interquartile range 0.1–5) with age at diagnosis of
15 years (IQR 5–36). Forty percent of patients expe-
rience a recurrent course, 40% chronic and 20%
chronic with exacerbations. Most attacks resolve with-
in 24 h (48%) but 36% can last more than 3 days. In
terms of systemic features, skin involvement was the
most commonly reported symptom (97%). Fever is
seen in 84% and arthralgia in 86%. Patients still tend
to be subdivided into FCAS, MWS and CINCA, al-
though it is becoming increasingly clear that there is
substantial overlap between these groups, and CAPS
is best regarded as a continuous rather than discrete
severity spectrum.
Familial cold autoinflammatory syndrome
Symptoms consistent with the FCAS phenotypemost commonly develop in the
first few years of life and are typified by fever, urticaria, conjunctival inflamma-
tion and arthralgia, which can occur from 30 min to 48 h following cold
exposure and resolve typically after a few hours. Secondary AA amyloidosis is
very rare in FCAS, but despite being the mildest CAPS phenotype, FCAS often
has a severe impact on patient quality of life with symptoms precluding
outdoor activities in over 95% of patients [9].
Muckle-Wells syndrome
MWS is now recognised to be an intermediate phenotype of CAPS characterised
by chronic or intermittent episodes of fever, headache, urticarial like rash, red
eyes, arthralgia or arthritis, often in the absence of a specific trigger [10]. Febrile
attacks commence in early childhood and patients often develop progressive
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sensorineural hearing loss. Approximately 25% of untreated patients develop
AA amyloidosis secondary to chronic inflammation [11].
Chronic infantile neurological cutaneous and articular syndrome
CINCA is viewed as the most severe CAPS phenotype [6]. In general,
children present during the first days of life with a chronic urticarial
rash associated with persistent low-grade fever and elevation of acute
phase reactants. Patients frequently have a typical facial appearance, with
frontal bossing, large cephalic perimeter and saddle-back nose [12••].
They develop permanent neurological damage with chronic aseptic men-
ingitis, raised intracranial pressure and hydrocephalus, brain atrophy and
chronic papilloedema [8••]. Chronic irritability, intellectual disability,
headache, lower limb spasticity and more rarely seizures can occur
[10]. There can be eye inflammation from anterior to posterior including
conjunctivitis, uveitis and optic neuritis. Papilloedema due to raised
intracranial pressure and optic neuritis can result in optic atrophy [13].
Cochlear inflammation leads to progressive stepwise sensorineural hear-
ing loss in the first years of life. Approximately 60% of patients have
prominent arthropathy, usually during childhood, causing deformity and
degenerative arthropathy leading to contractures [12••]. Mortality is
high, and death in childhood well recognised. Chronic inflammation
leads to the deposition of AA amyloid and renal failure [12••].
Molecular pathogenesis of CAPS
CAPS is caused by heterozygous gain-of-function mutations within the
NLRP3 gene, located on chromosome 1q44, which can be inherited in a
dominant fashion with variable penetrance and expression, or arise de
novo, the latter usually in CINCA. NLRP3 encodes cryopyrin, a member
of the intracellular nucleotide-binding oligomerisation domain-like re-
ceptors (NLRs). NLRs are pattern recognition receptors which recognise a
variety of pathogen-associated molecular pattern molecules (PAMPs)
[10]. All NLRs contain a NACHT domain (common to NAIP (neuronal
apoptosis inhibitory protein), CIITA (MHC class II transcription activa-
tor), HET-E (incompatibility locus protein from Podospora anserina) and
TP1 (telomerase-associated protein)) that regulates autoaggregation and
oligomerisation. Oligomerisation of cryopyrin results in activation of
caspase-1. This catalyses the cleavage of prointerleukin-1β to interleu-
kin-1β, and is the key step in its regulation. Interleukin-1β is a potent
proinflammatory cytokine with pleiotropic effects including fever, vaso-
dilatation and production/activation of other inflammatory cytokines
[7]. Mutations in NLRP3 therefore cause overactivation of the IL-1β
pathway, a cascade of complex cellular events and ultimately aberrant
homeostatic tissue responses (Fig. 1) [8••, 10].
Around 170 NLRP3 variants have been associated with CAPS. The
majority of mutations identified have been observed within exon 3, which
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is responsible for encoding the NACHT domain, crucial for cryopyrin
oligomerisation [12••]. In CINCA, mutations in other exons encoding
the leucine rich repeat PAMP recognition domain are also known. Al-
though patients with FCAS and MWS tend to show familial inheritance,
CINCA usually occurs de novo. Approximately 50–65% lack mutations in


















Fig. 1. Schematic representation of the NLRP3 inflammasome. The activation of NLRP3 by a variety of pathogen-associated
molecular pattern molecules interacting with the leucine-rich repeat (LRR) domain leads to aggregation and oligomerisation of a
molecular complex which in turn activates caspase-1, thereby promoting the production of the proinflammatory cytokine
interleukin-1β. In CAPS, gain-of-function mutations of NLRP3, often in the NACHT domain, result in overactivation of this pathway.
Other domains of the assembling macromolecule labelled in the diagram are CARD (caspase activation and recruitment domain),
PYD (pyrin domain) and FIIND (“function-to-find” domain).
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of these are mosaics for very damaging mutations, but other genes are also
likely to be implicated in the phenotype [12••].
Neurological manifestations of CAPS
The variety of neurological manifestations reported in the literature highlights
the importance of considering CAPS as a potential differential diagnosis in a
wide range of neurological presentations.
A selection of articles that report the neurological manifestations of CAPS is
summarised in Table 1. Key neurological features of CAPS include headache,
with a notably high proportion of patients with phenotypic features consistent
Table 1. Examples of papers describing neurological manifestations of CAPS (order of year of publication)
Citation Study type Key findings
[4] Patient cohort national referral centre (UK)
(n = 13)
• Headache present in 92% (77% had features of migraine)
• Sensorineural deafness present in 54%
• Myalgia reported in 69%
• 46% had papilloedema and 15% had optic disc pallor
[8••] Web-based Eurofever Registry (n = 136) • 40% classified as having neurological features (morning
headache, papilloedema and aseptic meningitis to seizures
and hydrocephalus)
• Ophthalmological involvement in 71% and sensorineural
hearing loss in 42%.
[14] Patient cohort (n = 17)—screening of 108
patients in neuroimmunology clinic
(Germany)
• 65% had severe headache syndromes (55% were diagnosed
with migraine)
• 53% had a concomitant diagnosis of multiple sclerosis
• 56% of those receiving treatment responded to
anti-interleukin-1 therapy.
[15] Single case report • Chorea associated with chronic white matter lesions on FLAIR
imaging with partial gadolinium enhancement
• Good response to anakinra
[2••] Patient cohort—national referral centre (UK)
(n = 38) (expanded cohort from ref. [4])
• 84% had some form of headache
• 66% sensorineural hearing loss
• 60% myalgia
• 34% papilloedema and 26% optic atrophy
• 90% of patients with headache responded to IL-1 inhibition
[16] Single case report • Unilateral orbital pain and diplopia with granulomatous
inflammation of both cavernous sinuses on brain MRI
consistent with Tolosa-Hunt syndrome
• CSF pleocytosis noted after lumbar puncture
• Only partial response to prednisolone
• Genetic testing revealed NLRP3 mutation
[3] Patient cohort—national referral centre
(France) (n = 24)
• 17 patients (71%) had neurological involvement
(predominantly headaches and hearing loss)
• 11 adult patients (61%) and 3 children (50%) had school
difficulties
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with migraine or chronic daily headache [2••, 3, 4]. In addition, more sinister
headache phenotypes with evidence of raised intracranial pressure and aseptic
meningitis have been reported [2••, 4, 8••]. Papilloedema is seen in around
30% of patients [2••, 3, 8••].
Sensorineural hearing loss occurs in approximately 40% of patients, many
requiring hearing aids or cochlear implantation. As hearing loss onset is often in
mid to late childhood, many of these patients acquire normal speech. Mild
ocular manifestations such as conjunctivitis (66%) or uveitis (7%) are frequent-
ly reported [8••]. Severe ocular involvement, including optic atrophy, cataract
and impaired vision, is less common [2••, 3, 4, 8••].
Although the numbers of patients are small, there is evidence that specific
genotypes may influence the extent to which neurological symptoms manifest.
Data from the cohort based in the UK suggested patients with the T348M
mutation tended to have a more severe neurological phenotype with an earlier
age of onset [2••]. Data from an observational study in France were consistent
with the UK data and found that the R260W mutation was more likely to be
associated with neurological involvement in patients compared to those with
the A439V mutation [3]. The E311K mutation is reported to be associated with
a higher rate of hearing loss [17].
In one interesting study, 108 patients in a neuroimmunology clinic were
screened for NLRP3 mutations on the basis of systemic symptoms compatible
with mild CAPS. The authors reported 17 (16%) patients had a V198M or Q703K
NLRP3 variant [14]. The interpretation of these variants is contentious as they occur
at a high frequency in the healthy population; V198M has an allele frequency of
0.007, and Q703K is seen in 10% of healthy controls. In vitro functional studies
have suggested that V198Mhas an intermediate effect on inflammasome activation
and IL-1β production compared to definite pathogenic mutations and wild-type
controls. Many of these patients reported neurological features (e.g. headache and
sensorineural hearing loss). Nine patients underwent anti-IL-1 therapy, with 5
reported to have responded to treatment [14].
A single case report recently described the diagnosis of CAPS in a patient
with Tolosa-Hunt syndrome after genetic testing [16], whilst another case report
highlighted chorea as a manifestation of CAPS [15]. Cognitive dysfunctionmay
also be a feature of CAPS, with a study from a specialist centre in France
reporting educational difficulties in the majority of adults (61%) and children
(50%) [3].
Management of CAPS
A suggested approach to the management of CAPS is shown in Table 2. Of
prime importance once a diagnosis is genetically confirmed is the institution of
disease modifying therapy in the form of IL-1 inhibition. Canakinumab is a
fully human anti-IL-1β monoclonal antibody administered as a subcutaneous
injection once every 8 weeks starting at a dose of 150 mg. In a double-blind
placebo-controlled randomised withdrawal study, there was evidence of a
complete response to canakinumab in 78% of drug-naive patients [18, 19].
Monitoring of systemic disease activity in the form of serum amyloid-A protein
(SAA) levels is the most sensitive marker of CAPS disease activity and predictor
of the risk of systemic AA amyloidosis. Ninety percent of patients treated with
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canakinumab showed complete normalisation of SAA by day 8 post treatment,
as well as concomitant decrease in C-reactive protein (CRP) and resolution of
symptoms [18, 19].
In addition to canakinumab, anakinra, a recombinant form of the IL-1
receptor antagonist, delivered as a daily dose of 100 mg via subcutaneous
injection [20], is also licensed in CAPS. Anakinra was the first commercially
available anti-IL-1 agent and has been shown to be effective against IL-1-driven
autoinflammatory disease [20, 21].
CAPS is a lifelong illness that affects women of child bearing age, and
optimal control of symptoms during pregnancy is of utmost importance for
the health of bothmother and foetus. There are safety data available for anakinra
in pregnancy [22]. An observational study of 15 pregnancies reported no pre-
term births or serious complications of pregnancy using anakinra throughout
gestation, whilst providing relief of CAPS symptoms. An international collabo-
rative study has reported that paternal exposure to IL-1 blockade appears un-
complicated in an experience of 12 cases to date. Maternal data on 23 women
exposed to anakinra and 8 exposed to canakinumab are generally reassuring but
the numbers remain small and there is concern about renal agenesis [23••].
Experience is that many patients are unable to discontinue treatment due to
rapid recurrence of autoinflammatory disease, and individual preconception risk
benefit discussion with prospective parents is strongly recommended.
As previously highlighted, headaches, and in particular migraine, are a com-
monneurologicalmanifestation of CAPS [2••, 3, 4].Migraines are also common
in the wider population [24] and may be unrelated to underlying CAPS pathol-
ogy. It is therefore important to correlate headache and other migrainous
Table 2. Key management recommendations for cryopyrin associated periodic fever syndrome (CAPS)
Recommendation Details
Referral to specialist centre • UK: The National Amyloidosis Centre, Royal Free Hospital, London http://www.ucl.ac.
uk/amyloidosis/nac
Genetic analysis • Genetic counselling
• Testing of NLRP3 gene
• Consideration of family member screening
Lifelong IL-1 inhibition • First line: subcutaneous injection of canakinumab every 8 weeks (starting dose 150 mg)
• Second line: subcutaneous injection of anakinra once daily (starting dose 100 mg)
Regular monitoring of
disease activity
• Quality of life questionnaire
• Serum amyloid A (SAA) measurement
• Serum C-reactive protein (CRP) measurement
Monitor for complications • Baseline neurological assessment with brain MRI (repeat brain MRI in those with
abnormalities and consideration of lumbar puncture depending on clinical presentation)
• Annual pure tone audiometry
• Annual ophthalmic assessment by ophthalmologist
• Serum amyloid P (SAP) scan if suggestion of systemic amyloidosis
Patient education • Clinical nurse specialists
• Online communities e.g. https://www.rareconnect.org/en/community/caps
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symptoms with systemic disease activity, and in many cases migraines may
resolve with disease modification [2••]. However, effective symptomatic and
preventative treatments for migraine and other primary headache disorders are
available and should be considered in addition to disease modification in CAPS
on a patient by patient basis, using international guidelines [25].
Hearing loss is a commonmanifestation of CAPS. A recent study where CAPS
patients underwent detailed auditory testing found that 100% of symptomatic
CAPS patients had high frequency pure tone averages abnormalities, whilst 74%
had an abnormal assessment focusing on standard frequencies (0.5–4 kHz)
[26]. Encouragingly, treatment with IL-1 blockade resulted in improved or stable
hearing in 91% of patients [26]. However, it is important to note that once
sensorineural damage has occurred, hearing dysfunction is likely irreversible.
This highlights the importance of regular and detailed auditory screening, as well
as early institution of disease modification to prevent CAPS-related hearing loss.
Beyond prevention, advances in hearing aids and cochlear implants are ongoing
[27], and obtaining the relevant opinions from otolaryngology and audiology
colleagues is of paramount importance in patients with established hearing loss.
Similarly, input from ophthalmology colleagues is crucial as eye involvement at
any level from the cornea to the optic nerve is common and can be sight
threatening [2••, 4, 8••]. We would recommend annual assessment in all cases,
with more frequent assessment if abnormalities are detected.
Although the majority of CAPS patients have clinically normal brain MRI
[2••, 4], cranial imaging can be helpful as white matter hyperintensities are
sometimes observed [2••, 3, 14, 15], and in some patients, have been reported
to improve after anti-IL-1 treatment [15]. Interestingly, in the aforementioned
cohort of patients from a neuroimmunology clinic, a much higher proportion
of patients (88%) had MRI brain abnormalities, often in the form of white
matter lesions [14].
In addition to the neurological manifestations, monitoring of systemic
symptoms is important. If there is a clinical suspicion of systemic AA amyloid-
osis, which can be ultimately life threatening in the form of end-stage renal
failure [11], a renal biopsy or serum amyloid P (SAP) nuclear medicine scan is
advised [28].
Management of CAPS is therefore complex and requires significant expertise
and multidisciplinary involvement. In the UK, a national service is provided by
the NHSNational Amyloidosis Centre based in London (http://www.ucl.ac.uk/
amyloidosis/nac) and referral to such centres is key to ensuring optimal
management.
Conclusions
Much is known about CAPS at amolecular and genetic level, but due to the non-
specific, chronic, relapsing-remitting nature of the condition, patients’ diagnosis
and treatment are often delayed. Once thought to be three separate entities,
CAPS is now considered a continuous clinical spectrum of a single condition,
with genotype-phenotype variations. Recurrent flares of fever, skin and joint
involvement and neurological symptoms should lead a clinician to consider the
diagnosis of CAPS, particularly in those with a positive family history. Neuro-
logical manifestations range from the most commonly occurring headache and
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sensorineural hearing impairment to severe features such as hydrocephalus and
aseptic meningitis. Systemic inflammatory markers are elevated during exacer-
bations, as are levels of serum amyloid A protein. MR imaging may show non-
specific white matter abnormalities. Diagnostic criteria with a sensitivity of 81%
and specificity of 94% have recently been proposed [29]. These include raised
inflammatory markers (CRP/SAA) plus at least two of six CAPS-typical symp-
toms (urticaria-like rash, cold-triggered episodes, sensorineural hearing loss,
musculoskeletal symptoms, chronic aseptic meningitis and skeletal abnormali-
ties) [29]. Diagnosis is confirmed by genetic testing for theNRLP3mutation. The
fully human anti-IL-1βmonoclonal antibody canakinumab or the recombinant
form of the IL-1 receptor antagonist anakinra are highly effective medications
preventing further episodes of systemic inflammation and transforming quality
of life, but will not reverse established damage such as hearing or visual impair-
ment. Symptomatic treatment of pain, headaches and skin rash should also be
provided. Identification of affected patients early in the course of the disease is
crucial to prevent irreversible damage or the development of AA amyloidosis.
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